MarketWatch
Cingulate stock skyrockets after ADHD treatment shows positive trial results
Shares of Cingulate Inc. (CING) skyrocketed 82.9% toward an 11-month high in active premarket trading Friday, after the biopharmaceutical company reported positive results from a trial of its attention deficit/hyperactivity disorder (ADHD) treatment. With trading volume spiking to over 3.2 million shares, compared with the full-day average of about 112,400 shares, the stock was the biggest gainer and most active listed on major U.S. exchanges. “We are developing CTx-1301 to be the first true, once-daily stimulant medication that treats ADHD over an entire active day, and crucial to this is ensuring a pharmacokinetic profile customized for the unique attributes of stimulant medications and ADHD, regardless of food intake,” said Chief Executive Shane Schaffer.
